000169060 001__ 169060
000169060 005__ 20240229133637.0
000169060 0247_ $$2doi$$a10.1093/eurjpc/zwab075
000169060 0247_ $$2pmid$$apmid:34060615
000169060 0247_ $$2ISSN$$a2047-4873
000169060 0247_ $$2ISSN$$a2047-4881
000169060 0247_ $$2altmetric$$aaltmetric:106870399
000169060 037__ $$aDKFZ-2021-01218
000169060 041__ $$aEnglish
000169060 082__ $$a610
000169060 1001_ $$00000-0003-0663-5843$$aHilvo, Mika$$b0
000169060 245__ $$aPrimary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts.
000169060 260__ $$aLondon [u.a.]$$bSage Publ.$$c2022
000169060 3367_ $$2DRIVER$$aarticle
000169060 3367_ $$2DataCite$$aOutput Types/Journal article
000169060 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1648719086_24556
000169060 3367_ $$2BibTeX$$aARTICLE
000169060 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169060 3367_ $$00$$2EndNote$$aJournal Article
000169060 500__ $$a2022 Mar 25;29(3):e128-e137
000169060 520__ $$aLow-density lipoprotein cholesterol (LDL-C) is an established causal driver of atherosclerotic cardiovascular disease (ASCVD), but its performance and age-dependency as a biomarker for incident events and mortality arising from ASCVD is less clear. The aim was to determine the value of LDL-C as a susceptibility/risk biomarker for incident coronary heart disease (CHD), ASCVD, and stroke events and deaths, for the age groups <50 and ≥50 years.The performance of LDL-C was evaluated in three cohorts, FINRISK 2002 (n = 7709), HUSK (n = 5431), and ESTHER (n = 4559), by Cox proportional hazards models, C-statistics, and net reclassification index calculations. Additionally, the hazard ratios (HRs) for the three cohorts were pooled by meta-analysis. The most consistent association was observed for CHD [95% confidence interval (CI) for HRs per standard deviation ranging from 0.99 to 1.37], whereas the results were more modest for ASCVD (0.96-1.18) due to lack of association with stroke (0.77-1.24). The association and discriminatory value of LDL-C with all endpoints in FINRISK 2002 and HUSK were attenuated in subjects 50 years and older [HRs (95% CI) obtained from meta-analysis 1.11 (1.04-1.18) for CHD, 1.15 (1.02-1.29) for CHD death, 1.02 (0.98-1.06) for ASCVD, 1.12 (1.02-1.23) for ASCVD death, and 0.97 (0.89-1.05) for stroke].In middle-aged and older adults, associations between LDL-C and all the studied cardiovascular endpoints were relatively weak, while LDL-C showed stronger association with rare events of pre-mature CHD or ASCVD death among middle-aged adults. The predictive performance of LDL-C also depends on the studied cardiovascular endpoint.
000169060 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169060 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169060 650_7 $$2Other$$aCholesterol
000169060 650_7 $$2Other$$aGuideline
000169060 650_7 $$2Other$$aLDL
000169060 650_7 $$2Other$$aPerformance
000169060 650_7 $$2Other$$aPrediction
000169060 650_7 $$2Other$$aRisk
000169060 7001_ $$00000-0002-3096-8165$$aDhar, Indu$$b1
000169060 7001_ $$00000-0003-0636-6567$$aLääperi, Mitja$$b2
000169060 7001_ $$00000-0002-0816-5075$$aLysne, Vegard$$b3
000169060 7001_ $$aSulo, Gehard$$b4
000169060 7001_ $$00000-0003-1386-1638$$aTell, Grethe S$$b5
000169060 7001_ $$aJousilahti, Pekka$$b6
000169060 7001_ $$00000-0002-4885-1010$$aNygård, Ottar K$$b7
000169060 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b8$$udkfz
000169060 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b9$$udkfz
000169060 7001_ $$00000-0001-9888-4278$$aLaaksonen, Reijo$$b10
000169060 773__ $$0PERI:(DE-600)2646239-4$$a10.1093/eurjpc/zwab075$$gp. zwab075$$n3$$pe128-e137$$tEuropean journal of preventive cardiology$$v29$$x2047-4881$$y2022
000169060 909CO $$ooai:inrepo02.dkfz.de:169060$$pVDB
000169060 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000169060 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000169060 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169060 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169060 9141_ $$y2021
000169060 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000169060 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000169060 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-19$$wger
000169060 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000169060 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000169060 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000169060 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000169060 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000169060 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000169060 980__ $$ajournal
000169060 980__ $$aVDB
000169060 980__ $$aI:(DE-He78)C070-20160331
000169060 980__ $$aUNRESTRICTED